The 60 Second Podcast

Greg Wolfond - CEO, Blue Sky Capital Corp

Matt McCoy

Send us a text

Canada produces some of the best research in the world - so why does so little of it turn into real products that help people?

In this episode of The 60 Second Podcast, Matt McCoy sits down with Greg Wolfond, CEO of Blue Sky Capital Corp and Founding Director of Give Back Health, to break down the real reason Canadian innovation stalls after the lab.

Greg explains the “risk gap” between discovery and commercialization, why capital and teams hesitate to step in, and what Canada must do now to turn world-class science into real-world solutions — built and funded here at home.

Big ideas. Clear answers. In under a minute.

00:00 — Matt McCoy
So Greg, Canada produces world-class research, yet commercialization of that often lags. Why do you think that is and how can we fix that?

00:07 — Greg Wolfond
There’s a huge gap between the great stuff that gets produced and actually getting it through. And part of it is risk. We’ve done the science — it works in a dish, it works in a mouse — but how do you get it into humans?

There just isn’t enough capital stepping up, or the right teams helping researchers get over that gap. They need help to de-risk the science, prove it works better, and attract companies willing to fund it.

That’s what Give Back is trying to do — fund these innovations, make them work in Canada, and make sure they give back to Canada so we can deliver cost-effective solutions for Canadians.

This is the moment. Canada needs to step up and start funding the incredible innovations we already have.